Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE) in the last three months.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.2, a high estimate of $26.00, and a low estimate of $4.00. Highlighting a 33.7% decrease, the current average has fallen from the previous average price target of $18.40.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Sage Therapeutics...